13:58:43 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMid Cap Stockholm
RaySearch Laboratories är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av mjukvarulösningar för sjukvårdsindustrin. Särskilt område där bolagets produkter används är inom cancervården. Bolagets produkter vidaresäljs som dosplanerings- respektive informationssystem. Olika funktioner inkluderar maskininlärning, beräkningshastighet, automatiserad planering, virtuell simulering, adaptiv terapi och digitala arbetsflöden. Produkterna används av ett flertal kliniker.


2022-05-25 Årsstämma 2022
2022-05-18 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning RAY B 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning RAY B 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-22 Ordinarie utdelning RAY B 0.00 SEK
2019-05-21 Årsstämma 2019
2019-05-09 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning RAY B 0.00 SEK
2018-05-29 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning RAY B 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-19 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Ordinarie utdelning RAY B 0.25 SEK
2016-05-17 Årsstämma 2016
2016-05-12 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-29 Ordinarie utdelning RAY B 0.00 SEK
2015-05-28 Årsstämma 2015
2015-05-08 Kvartalsrapport 2015-Q1
2015-02-12 Bokslutskommuniké 2014
2014-11-27 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-28 Ordinarie utdelning RAY B 0.00 SEK
2014-05-27 Årsstämma 2014
2014-05-16 Kvartalsrapport 2014-Q1
2014-02-13 Bokslutskommuniké 2013
2013-11-27 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-05-23 Ordinarie utdelning RAY B 0.00 SEK
2013-05-22 Årsstämma 2013
2013-05-16 Kvartalsrapport 2013-Q1
2013-02-14 Bokslutskommuniké 2012
2012-11-16 Kvartalsrapport 2012-Q3
2012-08-28 Kvartalsrapport 2012-Q2
2012-05-31 Ordinarie utdelning RAY B 0.00 SEK
2012-05-30 Årsstämma 2012
2012-05-23 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-11-24 Kvartalsrapport 2011-Q3
2011-05-26 Ordinarie utdelning RAY B 0.50 SEK
2011-05-25 Årsstämma 2011
2011-05-04 Kvartalsrapport 2011-Q1
2011-02-18 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-27 Kvartalsrapport 2010-Q2
2010-05-26 Ordinarie utdelning RAY B 0.50 SEK
2010-05-25 Årsstämma 2010
2010-05-11 Kvartalsrapport 2010-Q1
2009-11-20 Kvartalsrapport 2009-Q3
2009-08-27 Kvartalsrapport 2009-Q2
2009-05-27 Ordinarie utdelning RAY B 0.00 SEK
2009-05-26 Årsstämma 1
2009-05-15 Kvartalsrapport 2009-Q1
2008-06-25 Split RAY B 1:3
2003-06-10 Split RAY B 20:1
2021-02-23 07:45:00

"For full-year 2020, net sales declined 12 percent, mainly the result of lower license sales due to the COVID-19 pandemic. Operating loss totaled SEK -3 M (68) and cash flow was SEK 62 M (-3). Despite challenging market conditions, 2020 was a productive year as we significantly strengthened our product portfolio", says Johan Löf, CEO of RaySearch.

  • Order intake SEK 239.1 M (277.2)
  • Net sales SEK 159.8 M (234.5)
  • Operating loss SEK -14.6 M (22.5)
  • Loss after tax SEK -14.2 M (18.9)
  • Loss per share before/after dilution SEK -0.41 (0.55)
  • Cash flow SEK -21.5 M (7.8)
  • Order backlog SEK 1,161.3 M (1,155.2) at the end of the period
  • Order intake SEK 854.8 M (1,046.2)
  • Net sales SEK 651.6 M (741.6)
  • Operating loss SEK -3.5 M (68.2)
  • Loss after tax SEK -9.1 M (50.4)
  • Loss per share before/after dilution SEK -0.26 (1.47)
  • Cash flow SEK 61.9 M (-3.4)
  • The Board proposes that no dividend be paid for 2020
  • The RayStation[®] treatment planning system was sold to more leading cancer centers, including Centre Eugène Marquis in France, Taipei Medical University Hospital in Taiwan, Dankook University Hospital in South Korea, the Clatterbridge Cancer Centre in the UK, and Riverside Regional Medical Center in the US. In addition, Johns Hopkins Medicine in the US and Centre Antoine Lacassagne increased their existing RayStation installations.
  • In December, new versions of RaySearch's software were released - the RayStation 10B* treatment planning system, which now supports brachytherapy and offers a speed revolution in Monte Carlo dose calculation for proton therapy, and the RayCare 4B[®*] oncology information system, which can now connect to Varian TrueBeam[TM], offers improved integration with RayStation and supports multiple parallel treatments and workflows.
  • In December, the first version of the RayIntelligence* oncology analytics system was released, as well as the RayCommand* treatment control system, which obtained marketing authorization in several European countries.
  • The general market situation is continuously improving with continued recovery in Asia and signs of demand recovery in other regions. At the same time, a second or third wave of the pandemic is being registered in many countries and it is unclear how long it will take before the vaccination program has an effect. RaySearch therefore expects that the negative effects of the COVID-19 pandemic on the company's sales and earnings will continue for some months to come, mainly because orders may be delayed, but that these effects will normalize in 2021.
  • Management is monitoring the situation closely and is prepared to take action if needed.




CEO Johan Löf and CFO Peter Thysell will present RaySearch's year-end report for January-December 2020 at a teleconference to be held in English on Tuesday, February 23, 2021 between 4:00-4:30 p.m. CET.

For login details to the teleconference, please register on:
http://emea.directeventreg.com/registration/6166079 (http://emea.directeventreg.com/registration/6166079%C2%A0)


Johan Löf, President and CEO    Tel: +46 8 510 530 00              E-mail: johan.lof@raysearchlabs.com
Peter Thysell, CFO                      Tel: +46 70 661 05 59              E-mail: peter.thysell@raysearchlabs.com

[*] Marketing clearance is required in some markets.


RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare. In December 2020, the company also launched a new treatment control system, RayCommand, as well as the data anlytics system, RayIntelligence. RaySearch's software is currently used by more than 2,600 cancer centers in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed for trading on Nasdaq Stockholm since 2003.
More information about RaySearch is available at www.raysearchlabs.com